Table 1.
Patient characteristics
| Patients with stage 3–4 GI GVHD (n=116) N (%) |
|
|---|---|
| Patient age | |
| ≤18 years | 14 (12) |
| 19–39 years | 23 (20) |
| 40–59 years | 62 (53) |
| ≥ 60 years | 17 (15) |
| Donor/patient sex | |
| Female/male | 32 (28) |
| Other | 84 (72) |
| Diagnosis | |
| AML | 36 (31) |
| ALL | 6 (5) |
| MDS/MPD | 25 (22) |
| CML | 9 (8) |
| CLL | 5 (4) |
| HD | 7 (6) |
| NHL | 17 (15) |
| MM | 4 (3) |
| Other | 7 (6) |
| Donor type and HLA status | |
| Related donors HLA-identical | 47 (40) |
| HLA-mismatched | 0 |
| Unrelated donors HLA-matched | 44 (38) |
| HLA-mismatched | 25 (22) |
| Cell source | |
| Cord blood | 0 |
| Bone Marrow | 20 (17) |
| PBSC | 96 (83) |
| Conditioning regimen | |
| Reduced intensity | 48 (41) |
| Myeloablative | 68 (59) |
| Previous autologous HCT | |
| No | 97 (84) |
| Yes | 19 (16) |
| GVHD prophylaxis | |
| CNI | 5 (4) |
| CNI/Methotrexate | 54 (47) |
| CNI/MMF | 57 (49) |
| Other | 0 |
*
Abbreviations: ALL acute lymphoid leukemia, AML- acute myeloid leukemia, CLL- chronic lymphocytic leukemia, CML- chronic myeloid leukemia, CNI- calcineurin inhibitor, GI- gastrointestinal, GVHD- graft-vs-host disease, HCT- hematopoietic cell transplantation, HD- Hodgkin’s disease, HLA- human leukocyte antigen, MDS- myelodysplastic syndrome, MM- multiple myeloma, MMF- mycophenolate mofetil, NHL- non-Hodgkin’s lymphoma, PBSCperipheral blood stem cells.